Novo Nordisk has agreed to acquire Akero Therapeutics, a clinical-stage company that develops treatments for metabolic diseases, the company announced last week. Akero’s EFX pipeline Akero Therapeutics’ treatment for metabolic-dysfunction-associated steatohepatitis (MASH) “is closely linked with Novo Nordisk’s expertise in diabetes and obesity,” the press release stated. More than 40% of patients with MASH, formerly…
FTC cracks down on 100-plus ‘improper’ drug patents in comprehensive enforcement push
Under the leadership of Lina Khan, the Federal Trade Commission (FTC) has stepped up its enforcement actions, complicating its clearances of mergers, including Amgen’s acquisition of Horizon Therapeutics, which concluded in early October. Most recently, FTC has challenged what it deems are “improper” patent listings. At the receiving end of the FTC drug patent crackdown…